Skip to main content
PMC home page
PLOS Pathogens logoLink to PLOS Pathogens
. 2012 Apr 19;8(4):e1002599. doi: 10.1371/journal.ppat.1002599

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge

Thomas R Hird, Nicholas C Grassly 1,*
Editor: Raul Andino2
PMCID: PMC3330118  PMID: 22532797

Abstract

Inactivated poliovirus vaccine (IPV) may be used in mass vaccination campaigns during the final stages of polio eradication. It is also likely to be adopted by many countries following the coordinated global cessation of vaccination with oral poliovirus vaccine (OPV) after eradication. The success of IPV in the control of poliomyelitis outbreaks will depend on the degree of nasopharyngeal and intestinal mucosal immunity induced against poliovirus infection. We performed a systematic review of studies published through May 2011 that recorded the prevalence of poliovirus shedding in stool samples or nasopharyngeal secretions collected 5–30 days after a “challenge” dose of OPV. Studies were combined in a meta-analysis of the odds of shedding among children vaccinated according to IPV, OPV, and combination schedules. We identified 31 studies of shedding in stool and four in nasopharyngeal samples that met the inclusion criteria. Individuals vaccinated with OPV were protected against infection and shedding of poliovirus in stool samples collected after challenge compared with unvaccinated individuals (summary odds ratio [OR] for shedding 0.13 (95% confidence interval [CI] 0.08–0.24)). In contrast, IPV provided no protection against shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59–1.11]) or when given in addition to OPV, compared with individuals given OPV alone (summary OR 1.14 [95% CI 0.82–1.58]). There were insufficient studies of nasopharyngeal shedding to draw a conclusion. IPV does not induce sufficient intestinal mucosal immunity to reduce the prevalence of fecal poliovirus shedding after challenge, although there was some evidence that it can reduce the quantity of virus shed. The impact of IPV on poliovirus transmission in countries where fecal-oral spread is common is unknown but is likely to be limited compared with OPV.

Introduction

The development and licensing of inactivated poliovirus vaccine (IPV) in 1955 and subsequently of the live-attenuated oral poliovirus vaccine (OPV) in 1961 had an enormous impact on poliomyelitis in the Western world and raised the possibility of global eradication [1]. In 1988 the World Health Assembly adopted a resolution to eradicate poliomyelitis, which led to a successful global programme that has reduced the number of children paralysed by poliomyelitis from approximately 350,000 each year to 1,349 in 2010. Eradication of poliomyelitis though the use of these vaccines relies on herd immunity, whereby unimmunized children are less likely to become infected because neighboring children have been vaccinated. Eradication is achieved even if all children have not been successfully immunized so long as the average number of secondary infections generated by each infected individual (the “reproduction number”) is less than 1.

Critically important to the herd immunity effect is the degree of mucosal immunity offered by vaccination against infection and shedding of poliovirus. The success to date of the Global Polio Eradication Initiative (GPEI) in eliminating wild-type poliovirus transmission from most of the world can largely be ascribed to mass vaccination campaigns with OPV. This vaccine was chosen not only because of the ease of administration, but also because of its superior ability to induce local intestinal mucosal immunity [2]. Immunization with live-attenuated vaccine mimics natural infection and results in the induction of a local secretory antibody (IgA) response that is associated with a reduction in shedding of poliovirus from the intestine [3], [4]. In contrast, intramuscular injection of IPV induces serum antibodies but does not induce secretory IgA at the mucosal surfaces [3] and has a much more limited impact on the resistance of the intestine to infection [5]. However, IPV can induce gut-homing lymphocytes and an increase in the secretion of poliovirus-specific IgA among individuals who have been previously exposed to live-attenuated or wild-type poliovirus [6], [7]. The impact of this immune boosting on resistance of the intestine to infection is unknown.

After the eradication of wild-type polioviruses, coordinated global cessation of the use of OPV is envisaged to prevent vaccine-associated paralytic poliomyelitis and the emergence of vaccine-derived polioviruses [8]. The majority of higher-income and some middle-income countries that previously used OPV and have been free of indigenous wild-type poliovirus transmission for several years have already switched to IPV in their routine immunization schedules for these same reasons. At the time of OPV cessation, many other countries are likely to want to use IPV for a period of time to protect their population against potential outbreaks of vaccine-derived or wild-type poliovirus. For this reason the GPEI has supported an aggressive programme of research towards developing an “affordable” IPV. This has included dose-reduction strategies based on the addition of adjuvants, intradermal administration, or reduced schedules; development of safer poliovirus “seed” strains to allow manufacture of IPV in lower-income countries; and engagement with vaccine manufacturers to determine market size and supply capacity [9]–[11]. There have also been calls for IPV use in areas with persistent wild-type poliovirus transmission where OPV immunogenicity and effectiveness are compromised [12]. In these settings a dose of IPV could, it is argued, boost intestinal IgA better than an additional dose of OPV.

The increasingly significant role of IPV highlights the need for a better understanding of the impact of this vaccine, alone and in combination with OPV, on nasopharyngeal and intestinal mucosal immunity. Studies will be especially important in settings with efficient fecal-oral transmission of poliovirus where herd-protection through the use of IPV has never been adequately demonstrated [13].

Mucosal immunity to poliovirus in an individual can be assessed by measuring vaccine poliovirus shedding after administration of a “challenge” dose of OPV. This is considered a reasonable surrogate for immunity to infection with wild-type polioviruses after natural exposure, although the relationship between protection of the individual and prevention of transmission in the population is not well defined.

A large number of poliovirus challenge studies of variable size, location, and design have been published over the last 50 years. Although a number of clinical trials that examine the impact of IPV on mucosal immunity in tropical settings are currently under way, review of published studies from a variety of settings will also be fundamental in providing the evidence base on which countries can make their decisions about the optimal vaccination strategy—in the final stages of eradication and after global cessation of OPV use. A number of review articles have examined some of the larger OPV challenge studies [2], [14], [15], but we are not aware of any attempt at a systematic review of the large and heterogeneous group of published studies.

Here we present a systematic review of challenge studies that examine poliovirus shedding in secretions in the nasopharynx and in stool samples collected from individuals 5–30 days after administration of OPV. We present a meta-analysis of the odds of shedding poliovirus among studies that compared two or more vaccination schedules using IPV, OPV, or a combination of these vaccines. The implications for poliovirus vaccination policy are discussed.

Results

Identified Studies

A total of 1,981 published articles were identified in the PubMed and Web of Knowledge databases using the search terms described in the Methods, and a further six studies were identified from literature cited in key references (Figure 1). Screening the title and abstracts of these articles resulted in 171 potentially relevant papers, which were read in full-text to identify 31 studies of poliovirus shedding in stool and four of shedding in the nasopharynx that met the inclusion criteria for the analysis (Tables S1 and S2). One publication included studies from three different countries, and these are included in the systematic review as separate studies [16].

Figure 1. Flow diagram showing included studies according to PRISMA guidelines [46].

Figure 1

Open in a new tab

The number of published articles identified by the given search term for initial screening and the resulting studies identified and included in the systematic review and meta-analysis are shown.

Statistical Analysis

From the 31 studies of poliovirus shedding in stool, there were 22 studies that compared shedding after challenge with the same OPV among individuals with different vaccination histories (Table S1). Classification of these vaccination histories into unvaccinated, OPV-only, IPV-only, and combined schedules permitted comparison of OPV vaccinated with unvaccinated children (Figure 2), IPV vaccinated with unvaccinated children (Figure 3), OPV with IPV vaccinated children (Figure 4), and OPV vaccinated with combined OPV/IPV vaccinated children (Figure 5; combined schedules mainly involved simultaneous administration of IPV and OPV, see figure legend for details). Summary odds ratios (ORs) for these comparisons were calculated independently for each poliovirus serotype based on fixed (n = 7) or random (n = 4) effect models according to the significance of the χ2 test for heterogeneity. Only one study compared serotype 2 poliovirus shedding in OPV-only and OPV/IPV vaccinated individuals, and so a summary OR was not calculated (Figure 5). There was no evidence for an association between individual study ORs and study size. In total, results from 18 studies were included in the meta-analyses that compared different vaccination histories.

Figure 2. Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with unvaccinated individuals.

Figure 2

Open in a new tab

Odds ratios (ORs) and 95% confidence intervals for individual studies are indicated by the boxes and grey lines. The summary odds ratio for each serotype is given by a diamond with the 95% confidence interval (CI) indicated by its width. The χ2 test for heterogeneity among studies was significant for serotypes 2 and 3 (p-values 0.33, <0.001, and 0.001 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). Details of the studies included are given in Table S1. *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.

Figure 3. Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV compared with unvaccinated individuals.

Figure 3

Open in a new tab

Labeling as for Figure 2. The χ2 test for heterogeneity among studies was not significant for any serotype (p-values 0.11, 0.47, and 0.07) or for the overall odds ratio (p-value 0.10). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.

Figure 4. Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with IPV.

Figure 4

Open in a new tab

Labeling as for Figure 2. The χ2 test for heterogeneity among studies was significant for serotypes 1 and 3 (p-values<0.001, 0.79, and 0.01 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.

Figure 5. Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV in addition to OPV compared with individuals vaccinated with OPV only.

Figure 5

Open in a new tab

Labeling as for Figure 2. The schedule indicates the number and type of OPV doses received by both groups and the number of doses of IPV that were added in the intervention group. In two studies, IPV was administered simultaneously with OPV at 6, 10, and 14 weeks (Modlin et al. 1997 [47] and du Chatelet et al. 2003 [48]), and in one study IPV was administered before and at the same time as OPV (schedule was IPV, IPV/OPV, OPV, OPV at 2, 4, 6, 15 months; WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines 1997 [49]). The χ2 test for heterogeneity among studies for serotypes 1 and 3 was not significant for each serotype (p-values 0.13 and 0.08) or for the serotypes combined (p-value 0.14).

Only four studies that met the inclusion criteria for the systematic review examined poliovirus shedding in the nasopharynx after administration of OPV (Table S2). Two of these studies compared IPV vaccinated with OPV vaccinated children and one compared IPV vaccinated with unvaccinated children. Very few samples were positive for poliovirus in these studies, and there was insufficient power to compare the prevalence of poliovirus in the nasopharynx of children with different vaccination histories.

Discussion

Systematic review and meta-analysis of published studies confirms the large protective effect of prior immunization with OPV on shedding of poliovirus in the intestine following administration of a challenge dose of OPV. The odds of vaccine poliovirus shedding was significantly reduced among children immunized solely with OPV compared with unvaccinated children (overall OR 0.13 [95% CI 0.08–0.24]). In contrast, IPV had no significant impact on the prevalence of challenge poliovirus shedding in stool samples, either on its own or when added to an OPV schedule (overall ORs 0.81 [0.59–1.11] and 1.14 [0.82–1.58], respectively). The superior impact of OPV on intestinal mucosal immunity is confirmed by the meta-analysis of studies that directly compared schedules that exclusively used OPV or IPV (overall OR for OPV compared with IPV immunized children was 0.15 [0.08–0.27]).

Although IPV does not significantly reduce the prevalence of poliovirus shedding in stool samples collected after challenge, it may reduce the duration and quantity of virus shed compared with unvaccinated children. Five studies that quantified poliovirus shedding found a 63%–91% (or an absolute 0.43–1.0 log10) reduction in the mean quantity of poliovirus shed in stool samples collected from IPV vaccinated compared with unvaccinated children [5], [17]–[20] (Table S1). Three of these studies also examined the duration of shedding and two found a shorter period of shedding in IPV vaccinated children [17], [19]. Using data from one of these studies [17], it has been noted that the combined reduction in both the quantity and duration of vaccine poliovirus shedding would reduce the total amount of poliovirus shed during the course of an infection by approximately 95% [15]. Because IPV is unable to induce a secretory IgA response in the intestine of naïve individuals, it has been suggested that secondary exposure to OPV shed by vaccinated children or to wild-type poliovirus in the environment may have primed the mucosal immune response of children in some of these earlier studies. The effect of IPV could therefore be at least partially explained by boosting of secretory IgA among mucosally primed individuals [7]. However, the low prevalence of non-challenge poliovirus serotypes in stool samples collected during these studies suggests that mucosal priming was limited, and in the more recent study the possibility of secondary exposure to poliovirus was deliberately excluded [18]. The impact of IPV in these studies is perhaps more likely to relate to local immunity induced by IPV through transudation of serum IgG rather than induction of a local secretory IgA response [7].

There were insufficient studies that examined the impact of IPV or OPV on poliovirus shedding in the nasopharynx after administration of OPV to draw any conclusions. Three studies of wild-type poliovirus shedding in the nasopharynx after natural exposure during epidemics in the United States in 1956–1960 found a lower prevalence of shedding among children who had a history of vaccination with IPV [21]–[24]. This reduction in shedding was not apparent when stool samples were examined. However, interpretation of these studies is limited by their small size and the potential for confounding by age and socioeconomic status between IPV immunization status and the degree of exposure to wild-type poliovirus.

The relationship between reduced poliovirus shedding among vaccinated children observed in challenge studies and the impact of vaccination on wild-type or vaccine-derived poliovirus circulation is unknown and likely to vary significantly according to the characteristics of the population. Challenge with a high titer of attenuated vaccine (Sabin) poliovirus, which is homologous to the immunizing strain in the case of OPV vaccinees, is different than natural exposure to wild-type poliovirus, which has an estimated median infectious dose for humans of about 10 median tissue culture infectious doses (TCID50) compared with about 103 for Sabin polioviruses [25]. Furthermore, the relationship between the quantity of virus shed and the probability of onwards transmission is unknown and likely to depend on the importance of different routes of transmission and dissemination in the environment.

The impact of IPV on poliovirus circulation is expected to be more limited compared with OPV in areas with poor sanitation and efficient fecal-oral transmission because of the absence of any significant effect of this vaccine on the prevalence of poliovirus shedding in stool. However, there are no studies with adequate control populations that investigate the impact of IPV on wild-type poliovirus transmission in such areas [13]. Indeed, IPV has rarely been used in lower-income countries except as part of private practice. The recent switch to routine immunization with IPV in a pilot project in Yogyakarta in Indonesia and in a number of middle-income countries in South America may provide some information about the ability of IPV to prevent circulation of vaccine-derived polioviruses in areas with poor sanitation, given the continued use of OPV in neighboring areas or during national immunization days, respectively [26], [27].

In northern European countries (France, Netherlands, Sweden, Finland, Iceland), IPV schedules have resulted in the eradication of wild-type polioviruses and protected against large outbreaks of paralytic disease for several decades [28]. The impact of IPV in these countries has been attributed to an effect of IPV on shedding in the nasopharynx in settings where oral-oral transmission is likely to predominate. Where importations of wild-type polioviruses to these countries have been documented, they have resulted in outbreaks ranging from a single case to over 100 cases of poliomyelitis [29]–[32]. These outbreaks have usually been restricted to unvaccinated communities, indicating the reduction in poliovirus transmission that results from vaccination with IPV. To date, no outbreaks have been reported from countries that have recently switched to exclusive use of IPV. However, there is some evidence from Israel that IPV-using communities are more at risk compared with OPV-using communities [33]. Furthermore, asymptomatic wild poliovirus shedding has been detected among IPV vaccinated children during outbreaks in these European countries, albeit at lower frequencies than in unvaccinated children [32], [34]. IPV vaccinated children may therefore play a role in the circulation of imported wild poliovirus, and for this reason these outbreaks have usually been controlled through the reintroduction of OPV to induce adequate mucosal immunity to stop transmission.

In some of the comparisons of vaccination schedules, the meta-analysis identified significant heterogeneity in the OR from different studies. Heterogeneity is likely to arise from a number of sources, including variable times for sample collection after challenge, different numbers and timing of vaccine doses prior to challenge, and variable laboratory procedures, as well as unmeasured factors such as the prevalence of enteric infections that may interfere with vaccine poliovirus shedding. Indeed, the prevalence of challenge poliovirus shedding was highly variable among studies, even for those that examined very similar vaccination schedules (Table S1). There were insufficient studies to permit a formal meta-regression model that included these variables. However, we did examine some of them by stratifying the meta-analysis and present the results together with the number of doses of vaccine received prior to challenge because of the association of this variable with the prevalence of shedding (Figures 2– 5). For example, studies that compared poliovirus shedding among children who had received just a single dose of OPV with unvaccinated children typically found a limited impact on serotype 3 poliovirus, presumably because of the poor immunogenicity of a single dose of serotype 3 Sabin poliovirus, particularly in the trivalent formulation [35].

Despite over 50 years of vaccination with Salk's IPV, questions remain about the ability of this vaccine to prevent poliovirus circulation in remaining polio-endemic countries. In addition, basic immunology research is required to better understand the mucosal immune response to both IPV and OPV, and in particular the adaptive cellular and innate components [36], [37]. Recent evidence from India for waning intestinal immunity to poliovirus within a year of vaccination with OPV [38] and identification of wild-type polioviruses in stool samples from OPV immunized children [39] has generated interest in the potential for IPV to boost intestinal immunity among these children. Studies of immune boosting following IPV or OPV are therefore currently under way to assess the possible role for IPV in combination with OPV to interrupt wild-type poliovirus transmission in endemic countries. After eradication of wild-type polioviruses and global cessation of vaccination with OPV, the role of IPV in lower-income countries has yet to be defined. Research towards an affordable IPV aims to provide the option to use this vaccine during routine immunization and could protect children from poliomyelitis in the event of an outbreak of wild-type or vaccine-derived poliovirus. It is unknown whether this vaccine would limit the spread of poliovirus, but it would potentially provide the protection needed before an outbreak response using OPV. Continued research and programmatic use of IPV will eventually provide evidence for the impact of IPV on poliovirus circulation in countries with fecal-oral transmission of infection. It is hoped that this evidence will emerge in the context of successful global eradication of poliomyelitis.

Materials and Methods

Identification and Review of Studies

A literature search was carried out in May 2011 using the PubMed (http://www.ncbi.nlm.nih.gov) and ISI Web of Knowledge (http://isiknowledge.com) citation databases by searching title, abstract, and keywords with the search term “polio* and (shed* or excret* or stool or faece* or fece* or throat or naso*)”. The asterisk functions as a wildcard that permits partial word matching. We did not apply any language or publication restrictions except the restrictions of the databases themselves. Additionally, the bibliographies of key studies and reviews were examined to identify further relevant studies [2], [14], [40]. Publications in languages other than English that did not provide an English summary were translated by the authors or proficient speakers.

The titles and abstracts of articles identified by the initial search were screened and those that did not describe measures of poliovirus-specific immunity or shedding of vaccine poliovirus were removed. Full-text copies of the remaining articles were read using documents sourced from the original electronic journals or the holdings of the British Library. Data on the prevalence and quantity of vaccine poliovirus shed in nasopharyngeal or stool samples were extracted from those articles that met the inclusion criteria. These were: 1) study records the prevalence of vaccine poliovirus shedding in stool or nasopharyngeal samples collected after administration of a challenge dose of live-attenuated poliovirus; 2) samples collected 5–30 days after challenge (shedding of virus up to 4 days after challenge was excluded, because it has been suggested that this can be the result of transient passage of vaccine rather than infection of the mucosal surfaces [41]). Studies were excluded if they: 1) duplicated findings reported earlier; 2) included immuno-compromised individuals; 3) included fewer than 30 individuals; 4) included insufficient information describing poliovirus serotype, vaccine schedules prior to challenge, or prevalence of shedding by individual rather than by sample; 5) challenged with OPV more than 5 years after vaccination. These criteria ensured consistent information was available for all studies, minimizing the risk of selective reporting of favorable results within a study.

Data that were extracted from studies meeting the inclusion criteria were the vaccine type and schedule prior to challenge, challenge vaccine type and dose, the nature of the sample, and the laboratory methods (cell culture–based versus direct detection using real-time PCR). The number of individuals who shed or did not shed vaccine poliovirus was recorded by serotype and time of sample collection. Where samples were collected at multiple time points, these data were recorded separately. Data on the quantity of vaccine poliovirus shed based on titration of samples or quantitative PCR were recorded where available. We also recorded the mean duration of shedding when given or estimated this from the data where possible by taking the mean of an exponential curve fit to the prevalence of shedding over time using a least-squares approach. Data were extracted independently by the two authors and compared for errors before producing a consolidated database. Where reported data were incomplete, an effort was made to contact the authors of the relevant studies.

Statistical Analysis

We included challenge studies that compared shedding of challenge poliovirus across two or more vaccination schedules in a meta-analysis. Where stool samples were available for more than one time point, we used data from the sample taken closest to 7 days after challenge. For the purposes of the meta-analysis, schedules were grouped into four categories—unvaccinated, trivalent OPV only, IPV only, and combined schedules—and the relative odds of poliovirus shedding calculated in pairwise comparisons between these groups. There were insufficient studies of monovalent or bivalent OPV immunization schedules to warrant a separate category for these vaccines. We only compared combined schedules with OPV or IPV-only schedules where the combination schedule involved the administration of additional doses of IPV (we did not, for example, include studies that compared a schedule of six doses of trivalent OPV with a schedule of five doses of trivalent OPV and one dose of IPV, as examined in some studies, e.g., [42]). Evidence for heterogeneity among studies was assessed on the basis of the χ2 statistic [43]. Summary ORs and 95% confidence intervals were calculated on a log scale assuming either fixed effects or normally distributed random effects among studies according to the results of the χ2 test [44]. The association between the individual study ORs and study size was examined for evidence of potential publication bias. All analyses were implemented in the R programming language using the rmeta package [45].

Supporting Information

Checklist S1

PRISMA statement.

(DOC)

Click here for additional data file. (63KB, doc)
Table S1

Studies included in the systematic review that examined poliovirus shedding in stool samples taken after administration of OPV. Vaccination schedules are given as the number of doses followed by the type of vaccine. tOPV = trivalent OPV, mOPV1 = serotype 1 monovalent OPV, mOPV3 = serotype 3 monovalent OPV, bOPV2,3 = bivalent OPV containing serotypes 2 and 3. - = not available. Mean duration of shedding was estimated from the fit of an exponential curve to the prevalence of shedding over time unless given directly in the paper.

(DOCX)

Click here for additional data file. (122.4KB, docx)
Table S2

Studies included in the systematic review that examined poliovirus shedding in nasopharyngeal secretions after administration of OPV. Vaccination schedules are given as the number of doses followed by the type of vaccine. tOPV = trivalent OPV, mOPV1 = serotype 1 monovalent OPV.

(DOCX)

Click here for additional data file. (21.5KB, docx)

Acknowledgments

We thank the librarians at St Mary's Hospital for their assistance in obtaining full-text articles from the British Library and Roland Sutter for providing additional details for two studies.

Footnotes

NCG is a member of the WHO working group on IPV that reports to the Strategic Advisory Group of Experts (SAGE) on Immunization. Otherwise, the authors have declared that no competing interests exist.

This work was supported by a Royal Society University Research Fellowship and WHO Polio Research Committee grant to NCG (grant number 200245063). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Hinman AR, Foege WH, Dequadros CA, Patriarca PA, Orenstein WA, et al. The case for global eradication of poliomyelitis. Bull WHO. 1987;65:835–840. [PMC free article] [PubMed] [Google Scholar]
  • 2.Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull WHO. 1994;72:973–983. [PMC free article] [PubMed] [Google Scholar]
  • 3.Ogra PL, Karzon DT, Righthand F, MacGillivray M. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med. 1968;279:893–900. doi: 10.1056/NEJM196810242791701. [DOI] [PubMed] [Google Scholar]
  • 4.Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J Infect Dis. 2000;182:1–5. doi: 10.1086/315684. [DOI] [PubMed] [Google Scholar]
  • 5.Henry JL, Jaikaran ES, Davies JR, Tomlinson AJ, Mason PJ, et al. A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond) 1966;64:105–120. doi: 10.1017/s0022172400040389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Krieg C, Maier R, Meyerhans A. Gut-homing (alpha(4)beta(+)(7)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors. J Gen Virol. 2004;85:1571–1579. doi: 10.1099/vir.0.79919-0. [DOI] [PubMed] [Google Scholar]
  • 7.Herremans TM, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol. 1999;162:5011–5018. [PubMed] [Google Scholar]
  • 8.World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec. 2006;81:137–144. [PubMed] [Google Scholar]
  • 9.Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201:1344–1352. doi: 10.1086/651611. [DOI] [PubMed] [Google Scholar]
  • 10.Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362:2351–2359. doi: 10.1056/NEJMoa0909383. [DOI] [PubMed] [Google Scholar]
  • 11.Oliver Wyman Inc. Global post-eradication IPV supply and demand assessment: integrated findings. 2009. Commissioned by the Bill & Melinda Gates Foundation. Available: http://www.polioeradication.org/Research/AffordableIPV.aspx. Accessed 21 March 2012.
  • 12.Ehrenfeld E, Glass RI, Agol VI, Chumakov K, Dowdle W, et al. Immunisation against poliomyelitis: moving forward. Lancet. 2008;371:1385–1387. doi: 10.1016/S0140-6736(08)60597-8. [DOI] [PubMed] [Google Scholar]
  • 13.John TJ. Immunisation against polioviruses in developing countries. Rev Med Virol. 1993;3:149–160. [Google Scholar]
  • 14.Alexander JP, Jr, Gary HE, Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis. 1997;175(suppl. 1):S176–S182. doi: 10.1093/infdis/175.supplement_1.s176. [DOI] [PubMed] [Google Scholar]
  • 15.Sutter RW, Patriarca PA. Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. In: Kurstak E, editor. Measles and poliomyelitis. Springer-Verlag; 1993. [Google Scholar]
  • 16.World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine - a prospective evaluation in Brazil and the Gambia. J Infect Dis. 1995;171:1097–1106. doi: 10.1093/infdis/171.5.1097. [DOI] [PubMed] [Google Scholar]
  • 17.Ghendon YZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virol. 1961;5:265–273. [Google Scholar]
  • 18.Galindo M, Lago PM, Caceres V, Landaverde M, Sutter R (Cuba IPV Study Collaborative Group) Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. New Engl J Med. 2007;356:1536–1544. doi: 10.1056/NEJMoa054960. [DOI] [PubMed] [Google Scholar]
  • 19.Laassri M, Lottenbach K, Belshe R, Wolff M, Rennels M, et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis. 2005;192:2092–2098. doi: 10.1086/498172. [DOI] [PubMed] [Google Scholar]
  • 20.Enders-Ruckle G, Siegert R. [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)]. Dtsch Med Wochenschr. 1961;86:1999–2008. doi: 10.1055/s-0028-1113045. [DOI] [PubMed] [Google Scholar]
  • 21.Marine WM, Chin TDY, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg. 1962;76:173–195. doi: 10.1093/oxfordjournals.aje.a120272. [DOI] [PubMed] [Google Scholar]
  • 22.Wehrle PF, Reichert R, Carbonaro O, Portnoy B. Influence of prior active immunization on the presence of poliomyelitis virus in the pharynx and stools of family contacts of patients with paralytic poliomyelitis. Pediatrics. 1958;21:353–361. [PubMed] [Google Scholar]
  • 23.Wehrle PF, Carbonaro O, Day PA, Whalen JP, Reichert R, et al. Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. Pediatrics. 1961;27:762–764. [PubMed] [Google Scholar]
  • 24.Davis DC, Lipson MJ, Carver DH, Melnick JL, Robbins FC. The degree and duration of poliomyelitis virus excretion among vaccinated household contacts of clinical cases of poliomyelitis. Pediatrics. 1958;22:33–40. [PubMed] [Google Scholar]
  • 25.Dowdle W, Van der Avoort H, de Gourville E, Delpeyroux F, Desphande J, et al. Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Analysis. 2006;26:1449–1469. doi: 10.1111/j.1539-6924.2006.00844.x. [DOI] [PubMed] [Google Scholar]
  • 26.World Health Organization. Polio eradication: surveys of routine immunization coverage and seroprevalence against polioviruses, Yogyakarta Province, Indonesia. Wkly Epidemiol Rec. 2008;83:45–48. [PubMed] [Google Scholar]
  • 27.Troy SB, Ferreyra-Reyes L, Huang CH, Mahmud N, Lee YJ, et al. Use of a novel real-time PCR assay to detect oral polio vaccine shedding and reversion in stool and sewage samples after a Mexican national immunization day. J Clin Microbiol. 2011;49:1777–1783. doi: 10.1128/JCM.02524-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine. 1996;14:735–746. doi: 10.1016/0264-410x(95)00211-i. [DOI] [PubMed] [Google Scholar]
  • 29.Bijkerk H. Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand. 1979;43:195–206. [PubMed] [Google Scholar]
  • 30.van der Avoort HGA, Reimerink JHJ, Ras A, Mulders MN, van Loon AM. Isolation of epidemic poliovirus from sewage during the 1992-3 type-3 outbreak in the Netherlands. Epidemiol Infect. 1995;114:481–491. doi: 10.1017/s0950268800052195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Hovi T, Cantell K, Huovilainen A, Kinnunen E, Kuronen T, et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet. 1986;1:1427–1432. doi: 10.1016/s0140-6736(86)91566-7. [DOI] [PubMed] [Google Scholar]
  • 32.Bottiger M, Mellin P, Romanus V, Soderstrom H, Wesslen T, et al. Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden. Bull WHO. 1979;57:99–103. [PMC free article] [PubMed] [Google Scholar]
  • 33.Slater PE, Orenstein WA, Morag A, Avni A, Handsher R, et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet. 1990;335:1192–1198. doi: 10.1016/0140-6736(90)92705-m. [DOI] [PubMed] [Google Scholar]
  • 34.Oostvogel PM, Rumke HC, Conyn-van Spaendonck MAE, van der Avoort H, Leeuwenburg J, et al. Poliovirus circulation among schoolchildren during the early phase of the 1992–1993 poliomyelitis outbreak in The Netherlands. J Infect Dis. 2001;184:1451–1455. doi: 10.1086/324327. [DOI] [PubMed] [Google Scholar]
  • 35.Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Rev Infect Dis. 1991;13:926–939. doi: 10.1093/clinids/13.5.926. [DOI] [PubMed] [Google Scholar]
  • 36.Nathanson N. The pathogenesis of poliomyelitis: What we don't know. In: Maramorosch K, Shatkin AJ, Murphy FA, editors. Advances in virus research. Volume 71. San Diego: Elsevier Academic Press Inc; 2008. pp. 1–50. [DOI] [PubMed] [Google Scholar]
  • 37.Wahid R, Cannon MJ, Chow M. Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J Virol. 2005;79:5988–5995. doi: 10.1128/JVI.79.10.5988-5995.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Grassly NC, Jafari H, Bahl S, Sethi R, Deshpande JM, et al. Waning intestinal immunity following vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012 doi: 10.1093/infdis/jis241. In press. [DOI] [PubMed] [Google Scholar]
  • 39.Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, et al. Asymptomatic wild poliovirus infection in India among children previously immunized with oral poliovirus vaccine. J Infect Dis. 2010;201:1535–1543. doi: 10.1086/651952. [DOI] [PubMed] [Google Scholar]
  • 40.World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec. 2010;85:213–228. [PubMed] [Google Scholar]
  • 41.Krugman S, Warren J, Eiger MS, Berman PH, Michaels RM, et al. Immunization with live attenuated poliovirus vaccine. Am J Dis Child. 1961;101:23–29. doi: 10.1001/archpedi.1961.04020020025005. [DOI] [PubMed] [Google Scholar]
  • 42.Sutter RW, Suleiman AJM, Malankar P, Al-Khusaiby S, Mehta F, et al. Trial of a supplemental dose of four poliovirus vaccines. New Engl J Med. 2000;343:767–773. doi: 10.1056/NEJM200009143431103. [DOI] [PubMed] [Google Scholar]
  • 43.Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. The Cochrane Collaboration. Available: http://www.cochrane-handbook.org. Accessed 21 March 2012.
  • 44.Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 45.R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2010. ISBN: 3-900051-07-0. [Google Scholar]
  • 46.Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097. doi: 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine - Live attenuated oral poliovirus vaccine immunization schedules. J Infect Dis. 1997;175:S228–S234. doi: 10.1093/infdis/175.supplement_1.s228. [DOI] [PubMed] [Google Scholar]
  • 48.du Chatelet IP, Merchant AT, Fisher-Hoch S, Luby SP, Plotkin SA, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine. 2003;21:1710–1718. doi: 10.1016/s0264-410x(02)00523-6. [DOI] [PubMed] [Google Scholar]
  • 49.WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis. 1997;175(suppl. 1):S215–S227. doi: 10.1093/infdis/175.supplement_1.s215. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Checklist S1

PRISMA statement.

(DOC)

Click here for additional data file. (63KB, doc)
Table S1

Studies included in the systematic review that examined poliovirus shedding in stool samples taken after administration of OPV. Vaccination schedules are given as the number of doses followed by the type of vaccine. tOPV = trivalent OPV, mOPV1 = serotype 1 monovalent OPV, mOPV3 = serotype 3 monovalent OPV, bOPV2,3 = bivalent OPV containing serotypes 2 and 3. - = not available. Mean duration of shedding was estimated from the fit of an exponential curve to the prevalence of shedding over time unless given directly in the paper.

(DOCX)

Click here for additional data file. (122.4KB, docx)
Table S2

Studies included in the systematic review that examined poliovirus shedding in nasopharyngeal secretions after administration of OPV. Vaccination schedules are given as the number of doses followed by the type of vaccine. tOPV = trivalent OPV, mOPV1 = serotype 1 monovalent OPV.

(DOCX)

Click here for additional data file. (21.5KB, docx)

Articles from PLoS Pathogens are provided here courtesy of PLOS

RESOURCES